These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

458 related articles for article (PubMed ID: 27535394)

  • 21. Pemetrexed Singlet Versus Nonpemetrexed-Based Platinum Doublet as Second-Line Chemotherapy after First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Failure in Non-small Cell Lung Cancer Patients with EGFR Mutations.
    Park S; Keam B; Kim SH; Kim KH; Kim YJ; Kim JS; Kim TM; Lee SH; Kim DW; Lee JS; Heo DS
    Cancer Res Treat; 2015 Oct; 47(4):630-7. PubMed ID: 25687850
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase 2 study of bevacizumab in combination with carboplatin and paclitaxel in patients with non-squamous non-small-cell lung cancer harboring mutations of epidermal growth factor receptor (EGFR) after failing first-line EGFR-tyrosine kinase inhibitors (HANSHIN Oncology Group 0109).
    Hattori Y; Satouchi M; Shimada T; Urata Y; Yoneda T; Mori M; Nishimura T; Sunadome H; Kumagai T; Imamura F; Fujita S; Kaji R; Hata A; Tachihara M; Morita S; Negoro S
    Lung Cancer; 2015 Feb; 87(2):136-40. PubMed ID: 25553650
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer.
    Govindan R; Mandrekar SJ; Gerber DE; Oxnard GR; Dahlberg SE; Chaft J; Malik S; Mooney M; Abrams JS; Jänne PA; Gandara DR; Ramalingam SS; Vokes EE
    Clin Cancer Res; 2015 Dec; 21(24):5439-44. PubMed ID: 26672084
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessment of cytology based molecular analysis to guide targeted therapy in advanced non-small-cell lung cancer.
    Li W; Zhang Z; Guo L; Qiu T; Ling Y; Cao J; Guo H; Zhao H; Li L; Ying J
    Oncotarget; 2016 Feb; 7(7):8332-40. PubMed ID: 26789109
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI.
    Klempner SJ; Bazhenova LA; Braiteh FS; Nikolinakos PG; Gowen K; Cervantes CM; Chmielecki J; Greenbowe JR; Ross JS; Stephens PJ; Miller VA; Ali SM; Ou SH
    Lung Cancer; 2015 Sep; 89(3):357-9. PubMed ID: 26187428
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel drugs against non-small-cell lung cancer.
    Pirker R
    Curr Opin Oncol; 2014 Mar; 26(2):145-51. PubMed ID: 24406751
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non-small cell lung cancer harboring wild-type epidermal growth factor receptor: a meta-analysis.
    Lee JK; Hahn S; Kim DW; Suh KJ; Keam B; Kim TM; Lee SH; Heo DS
    JAMA; 2014 Apr; 311(14):1430-7. PubMed ID: 24715074
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Emerging protein kinase inhibitors for non-small cell lung cancer.
    Liu SV; Subramaniam D; Cyriac GC; Abdul-Khalek FJ; Giaccone G
    Expert Opin Emerg Drugs; 2014 Mar; 19(1):51-65. PubMed ID: 24354593
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?
    Ou SH; Soo RA
    Drug Des Devel Ther; 2015; 9():5641-53. PubMed ID: 26508839
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeted therapies for ROS1-rearranged non-small cell lung cancer.
    Patil T; Simons E; Mushtaq R; Pacheco JM; Doebele RC; Bowles DW
    Drugs Today (Barc); 2019 Oct; 55(10):641-652. PubMed ID: 31720561
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Overcoming crizotinib resistance in ALK-rearranged NSCLC with the second-generation ALK-inhibitor ceritinib.
    Muller IB; De Langen AJ; Honeywell RJ; Giovannetti E; Peters GJ
    Expert Rev Anticancer Ther; 2016; 16(2):147-57. PubMed ID: 26654422
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Beyond EGFR and ALK inhibition: unravelling and exploiting novel genetic alterations in advanced non small-cell lung cancer.
    Califano R; Abidin A; Tariq NU; Economopoulou P; Metro G; Mountzios G
    Cancer Treat Rev; 2015 May; 41(5):401-11. PubMed ID: 25842168
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic factors in non-small cell lung cancer patients who are recommended to receive single-agent chemotherapy (docetaxel or pemetrexed) as a second- or third-line chemotherapy: in the era of oncogenic drivers and molecular-targeted agents.
    Shukuya T; Ko R; Mori K; Kato M; Yagishita S; Kanemaru R; Honma Y; Shibayama R; Koyama R; Shimada N; Takahashi K
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):771-6. PubMed ID: 26259641
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A safety assessment of crizotinib in the treatment of ALK-positive NSCLC patients.
    Dikopf A; Wood K; Salgia R
    Expert Opin Drug Saf; 2015 Mar; 14(3):485-93. PubMed ID: 25659177
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Necitumumab: a new option for first-line treatment of squamous cell lung cancer.
    Jiménez Aguilar E; Zugazagoitia Fraile J; Paz-Ares Rodríguez L
    Expert Opin Drug Metab Toxicol; 2018 Aug; 14(8):765-772. PubMed ID: 30025476
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer.
    O'Bryant CL; Wenger SD; Kim M; Thompson LA
    Ann Pharmacother; 2013 Feb; 47(2):189-97. PubMed ID: 23386065
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeted therapies for treatment of non-small cell lung cancer--Recent advances and future perspectives.
    Minguet J; Smith KH; Bramlage P
    Int J Cancer; 2016 Jun; 138(11):2549-61. PubMed ID: 26537995
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Research Progress of Targeted Therapy for BRAF Mutation 
in Advanced Non-small Cell Lung Cancer].
    Liu X; Zhong D
    Zhongguo Fei Ai Za Zhi; 2018 Aug; 21(8):635-640. PubMed ID: 30172272
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identifying activating mutations in the EGFR gene: prognostic and therapeutic implications in non-small cell lung cancer.
    Lopes GL; Vattimo EF; Castro Junior Gd
    J Bras Pneumol; 2015; 41(4):365-75. PubMed ID: 26398757
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lung cancers with concomitant EGFR mutations and ALK rearrangements: diverse responses to EGFR-TKI and crizotinib in relation to diverse receptors phosphorylation.
    Yang JJ; Zhang XC; Su J; Xu CR; Zhou Q; Tian HX; Xie Z; Chen HJ; Huang YS; Jiang BY; Wang Z; Wang BC; Yang XN; Zhong WZ; Nie Q; Liao RQ; Mok TS; Wu YL
    Clin Cancer Res; 2014 Mar; 20(5):1383-92. PubMed ID: 24443522
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.